Cardiometabolic risk factors in people with psychotic disorders: The second Australian survey of psychosis: Going back to the foundations

Australian and New Zealand Journal of Psychiatry

Volumn 46, Issue 9, 2012, Pages 901-903

  Baptista, Trino ^a  

^a Universidad De Los Andes Facultad de Medicina   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; METFORMIN; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; VALPROIC ACID;

AUSTRALIA; BIPOLAR MANIA; CARDIOMETABOLIC RISK; DELUSIONAL DISORDER; DEPRESSIVE PSYCHOSIS; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; HUMAN; MENTAL HEALTH SERVICE; METABOLIC SYNDROME X; NOTE; POPULATION RESEARCH; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; FEMALE; MALE;

FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; PSYCHOTIC DISORDERS;

EID: 84873743508     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412457088     Document Type: Note

References (22)

1. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005 ; 54: 862-871
2. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry. 1999 ; 156: 1686-1696
3. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry. 2008 ; 193: 101-107
4. Baptista T, Serrano A, Uzcátegui E, et al. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela. Schizophrenia Research. 2011 ; 126: 93-102
5. De Hert MCC, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophrenia Research. 2010 ; 117: 68-74
6. De León J. Evidence-based medicine versus personalized medicine: are they enemies?. Journal of Clinical Psychopharmacology. 2012 ; 32: 153-164
7. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin. 2000 ; 26: 903-912
8. Donohoe DR, Jarvis RA, Weeks K, et al. Behavioral adaptation in C. elegans produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition. Neuroscience Research. 2009 ; 64: 208-289
9. Fernández E, Carrizo E, Fernandez V, et al. Polimorphisms of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. Schizophrenia Research. 2010 ; 121: 213-217
10. Fernandez E, Carrizo E, Connell L, et al. Pro12Ala polymorphism in PPARg2 gene, the metabolic syndrome and response to metformin in clozapine-treated patients. Schizophrenia Research. 2012 ; 137: 262-263
11. Francey SM, Nelson B, Thompson A, et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophrenia Research. 2010 ; 119: 1-10
12. Galletly CA, Folley D, Waterreus A, et al. Cardiometabolic risk factors in people with psychotic disorders: The second Australian survey of psychosis. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 753-761
13. Lee AK, Bishop JR. Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. Pharmacogenomics. 2011 ; 12: 999-1016
14. Maayan L, Vakhusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010 ; 35: 1520-1530
15. Mathews J, Newcomer JW, Mathews JR, et al. Neural correlates of weight gain with olanzapine. Archives of General Psychiatry. 2012 ;:
16. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research. 2005 ; 80: 19-32
17. Plananski K. Changes in weight in patients receiving a tranquilizing drug. The Psychiatric Quarterly. 1958 ; 32: 289-303
18. Remington G, Mann S, McCormick P, et al. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. Pharmacology Biochemistry and Behavior. 2011 ; 100: 86-89
19. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. British Journal of Psychiatry. 1988 ; 153: 214-217
20. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophrenia Bulletin. 1995 ; 21: 463-472
21. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 ; 374: 620-627
22. Windemuth A, de Leon J, Goethe JW, et al. Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2012 ; 36: 213-219